Using bispecific antibodies targeting specific tumor antigens (CD123 and BCMA) and CD3, we observed that co-culture of AML or MM cell lines with bone marrow stromal cells significantly protected cancer cells from bispecific-T-cell-mediated lysis in vitro. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.